Can India's Biocon land a global partner for its new psoriasis drug?
Biocon’s Kiran Mazumdar-Shaw has been one of the leaders in India attempting to build a biotech community capable of developing drugs for worldwide markets. Now the company has a test case on its hands. After gaining an approval in India for the homegrown psoriasis drug Alzumab, Mazumdar-Shaw has set out to find a pharma partner capable of pulling off the clinical trials needed for U.S. and European approvals.
The anti-inflammatory antibody, also known as itolizumab, was approved in the sub-continent based on data from a Phase III clinical trial with only 200 patients. And Mazumdar-Shaw has been touting it to Bloomberg as a likely competitor to some mega-blockbuster competition like Humira, Enbrel and Stelara.
«We have such long remission rates, compared to all the other drugs," Mazumdar-Shaw gushed to the business news wire. «We don’t even have relapse in many of the patients. After 24 weeks, we’re still not seeing relapse for a large percentage. That’s why we’re excited, that’s why this is a crown jewel for us." And she noted that the antibody has even bigger potential in rheumatoid arthritis.